VistaGen Therapeutics
VTGN
12 hedge funds and large institutions have $6.27M invested in VistaGen Therapeutics in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.67% more ownership
Funds ownership: 0% → 0.67% (+0.67%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
8% less funds holding
Funds holding: 13 → 12 (-1)
16% less capital invested
Capital invested by funds: $7.45M → $6.27M (-$1.18M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$221K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$146K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$671K |
| 2 |
Goldman Sachs
New York
|
-$51K |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
-$33.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
1
Sphera Funds Management
Tel Aviv,
Israel
| $2.03M | – | – | – |
|
|
NLVP
2
New Leaf Venture Partners
New York
| $1.32M | – | – | – |
|
|
3
Parallax Volatility Advisers
San Francisco,
California
| $1.06M | -$33.2K | -285 | -3% |
|
|
SM
4
Sabby Management
Miami Beach,
Florida
| $658K | -$671K | -5,758 | -49% |
|
|
NC
5
Nexthera Capital
New York
| $515K | – | – | – |
|
|
DADC
6
D.A. Davidson & Co
Great Falls,
Montana
| $324K | +$221K | +1,900 | +190% |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $140K | +$146K | +1,255 | New |
|
8
Geode Capital Management
Boston,
Massachusetts
| $112K | – | – | – |
|
9
HighTower Advisors
Chicago,
Illinois
| $75K | – | – | – |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $36K | – | – | – |
|
|
HFM
11
Hartford Financial Management
Hartford,
Connecticut
| $5K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $4K | +$1.05K | +9 | +35% |
|
|
13
Goldman Sachs
New York
| – | -$51K | -406 | Closed |
|
VTGN Hedge Fund Activity: Q4 2016 in Review
12 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2016, worth a combined $6.27M — down 16% from $7.45M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of VTGN and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was D.A. Davidson & Co, adding an estimated $221K. The largest seller was Sabby Management, cutting an estimated $671K.
- 12 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2016, down from 13 in Q3 2016.
- Funds reported $6.27M of VistaGen Therapeutics stock for Q4 2016, down 16% quarter-over-quarter.
- 1 fund opened new VistaGen Therapeutics positions in Q4 2016 and 2 closed out, a net change of -1 holder.
- The largest VistaGen Therapeutics buyer in Q4 2016 was D.A. Davidson & Co, an estimated $221K added.
- The largest VistaGen Therapeutics seller in Q4 2016 was Sabby Management, an estimated $671K sold.
Based on aggregated 13F filings for Q4 2016.